48 results about "Simian immunodeficiency virus" patented technology

The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The present invention is directed to vaccine compositions that can be used to protect cats against feline immunodeficiency virus. More particularly, the present invention relates to polynucleotide molecules that can be used as vaccine components against feline immunodeficiency virus.

The present invention is directed to vaccine compositions that can be used to protect cats against feline immunodeficiency virus. More particularly, the present invention relates to polynucleotide molecules that can be used as vaccine components against feline immunodeficiency virus.

This invention relates to compositions for the treatment of acquired immunodeficiency diseases, especially human immunodeficiency virus (HIV), and its simian and feline counterparts (simian immunodeficiency virus (SIV), and feline immunodeficiency virus (FIV)), and to methods for their use.

This invention relates to C34 peptide derivatives having improved aqueous solubility that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory synctial vims (RSV), human parainfluenza virus (HPV), measles virus (MeV). and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

This invention relates to a process for producing a Simian Immunodeficiency Virus (SIV) encoding a heterologous gene, which process comprises infecting a host cell with a first vector which is capable of producing SIV capsid and a second vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal sufficient to package the second vector in the SIV capsid and a heterologous gene capable of being expressed by the vector; and culturing the host cell.

The invention discloses a method for extracting antiviral active substance from phellinus igniarius, which relates to a method for extracting active substance from traditional Chinese medicine. The method includes the following steps that: phellinus igniarius fruit bodies are dehydrated and ground under low temperature; ethyl acetate which is 2 to 10 times as large as the volume of the ground fruit bodies is added in the ground fruit bodies to carry out extraction, ultrasonic oscillation is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder A. 90 percent of ethanol which is 2 to 10 times as large as the volume of filter residue extracted by the ethyl acetate is added into the filter residue to carry out extraction, ultrasonicoscillation is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder B. Water with the temperature of 20 DEG C, which is 5 to 30 times as large as the volume of filter residue extracted by the ethanol is added in the filter residue, ultrasonic extraction is carried out, filtrates are merged after filtration, and the filtrate is concentrated, frozen and dried into powder C. According to the weight percentage ratio of 10 percent to 80 percent : 10 percent to 80 percent : 10 percent to 80 percent, the powder A, the powder B and the powder C are uniformly mixed. The obtained active substance has a good effect in resisting simian immunodeficiency virus (SIV), herpes virus (HSV) and enterovirus (EV71).

Four glycoproteins of apparent molecular weights 300,000, 140,000, 125,000, and 36,000 (gp300, gp140, gp125, and gp36) are detectable in human immunodeficiency virus type 2 (HIV-2) infected cells. The gp125 and gp36 are the external and transmembrane components, respectively, of the envelope glycoproteins of HIV-2 mature virions. The gp300, which is a dimeric form of gp140, the precursor of HIV-2 envelope glycoprotein, is probably formed by a pH dependent fusion in the endoplasmic reticulum. Such a doublet is also observed in cells infected with simian immunodeficiency virus (SIV), a virus closely related to HIV-2. On the other hand, the envelope glycoprotein precursor of HIV-1 does not form a dimer during its processing. Experiments carried out with various inhibitors of oligosaccharide trimming enzymes suggest that transient dimerization of the glycoprotein precursor is required for its efficient transport to the Golgi apparatus and for its processing. The gp300 is useful for detecting antibodies to HIV-2 antigens in human body fluids and for raising antibodies to gp300.